Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male or female subjects, 6-12 years of age, inclusive, with a diagnosis of ADHD according to the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM IV), confirmed with the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID).~2. ADHD-RS-IV-Parent Version: Investigator Administered and Scored score of at least 26.~3. CGI-S score of at least 4~4. Weight of at least 20 kg.~5. Free of medication for the treatment of ADHD or any psychosis for at least one week prior to enrollment.~Exclusion Criteria:~1. Current or lifetime diagnosis of major depressive disorder, bipolar disorder, personality disorder, Tourette's disorder, or psychosis not otherwise specified.~2. Currently meeting DSM-IV criteria for pervasive developmental disorder, obsessive compulsive disorder, post-traumatic stress disorder, or any other anxiety disorder as primary diagnosis.~3. Significant systemic disease.~4. Evidence of suicidality within the six months before Screening or at Screening.~5. BMI greater than 95th percentile for the appropriate age and gender.~6. Pregnancy or refusal to practice abstinence during the study for female subjects of childbearing potential (FOCP).~7. Substance or alcohol use during the last three months.~8. Positive urine screen for cotinine, alcohol, or drugs of abuse at Screening.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, qd, oral capsule
- 100mg SPN-812 (Type: EXPERIMENTAL): 100mg SPN-812, qd, oral capsule
- 200mg SPN-812 (Type: EXPERIMENTAL): 200mg SPN-812, qd, oral capsule
- 300mg SPN-812 (Type: EXPERIMENTAL): 300mg SPN-812, qd, oral capsule
- 400mg SPN-812 (Type: EXPERIMENTAL): 400mg SPN-812, qd, oral capsule

Based on this trial design, predict the completion outcome and termination type (if applicable).